These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 27858912)

  • 1. A randomized controlled clinical trial on the impact of CCR5 blockade with maraviroc in early infection on T-cell dynamics.
    Karris MY; Umlauf A; Vaida F; Richman D; Little S; Smith D
    Medicine (Baltimore); 2016 Nov; 95(44):e5315. PubMed ID: 27858912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc.
    Chaillon A; Gianella S; Lada SM; Perez-Santiago J; Jordan P; Ignacio C; Karris M; Richman DD; Mehta SR; Little SJ; Wertheim JO; Smith DM
    J Virol; 2018 Feb; 92(3):. PubMed ID: 29142136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial.
    van Lelyveld SF; Drylewicz J; Krikke M; Veel EM; Otto SA; Richter C; Soetekouw R; Prins JM; Brinkman K; Mulder JW; Kroon F; Middel A; Symons J; Wensing AM; Nijhuis M; Borghans JA; Tesselaar K; Hoepelman AI;
    PLoS One; 2015; 10(7):e0132430. PubMed ID: 26208341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected.
    Gutiérrez C; Díaz L; Vallejo A; Hernández-Novoa B; Abad M; Madrid N; Dahl V; Rubio R; Moreno AM; Dronda F; Casado JL; Navas E; Pérez-Elías MJ; Zamora J; Palmer S; Muñoz E; Muñoz-Fernández MÁ; Moreno S
    PLoS One; 2011; 6(12):e27864. PubMed ID: 22174752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up.
    Ripa M; Pogliaghi M; Chiappetta S; Nozza S; Soria A; Coppalini G; Rovelli C; Tambussi G
    J Clin Virol; 2016 Dec; 85():86-89. PubMed ID: 27865174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.
    Serrano-Villar S; Sainz T; Ma ZM; Utay NS; Chun TW; Mann S; Kashuba AD; Siewe B; Albanese A; Troia-Cancio P; Sinclair E; Somasunderam A; Yotter T; Deeks SG; Landay A; Pollard RB; Miller CJ; Moreno S; Asmuth DM
    PLoS Pathog; 2016 Jan; 12(1):e1005381. PubMed ID: 26795282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial.
    Hunt PW; Shulman NS; Hayes TL; Dahl V; Somsouk M; Funderburg NT; McLaughlin B; Landay AL; Adeyemi O; Gilman LE; Clagett B; Rodriguez B; Martin JN; Schacker TW; Shacklett BL; Palmer S; Lederman MM; Deeks SG
    Blood; 2013 Jun; 121(23):4635-46. PubMed ID: 23589670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maraviroc intensification in patients with suppressed HIV viremia has limited effects on CD4+ T cell recovery and gene expression.
    Beliakova-Bethell N; Jain S; Woelk CH; Witt MD; Sun X; Lada SM; Spina CA; Goicoechea M; Rought SE; Haubrich R; Dubé MP
    Antiviral Res; 2014 Jul; 107():42-9. PubMed ID: 24769244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.
    Puertas MC; Massanella M; Llibre JM; Ballestero M; Buzon MJ; Ouchi D; Esteve A; Boix J; Manzardo C; Miró JM; Gatell JM; Clotet B; Blanco J; Martinez-Picado J;
    AIDS; 2014 Jan; 28(3):325-34. PubMed ID: 24185044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential CD4+ cell count increase and CD4+ :  CD8+ ratio normalization with maraviroc compared with tenofovir.
    Chan ES; Landay AL; Brown TT; Ribaudo HJ; Mirmonsef P; Ofotokun I; Weitzmann MN; Martinson J; Klingman KL; Eron JJ; Fichtenbaum CJ; Plants J; Taiwo BO
    AIDS; 2016 Aug; 30(13):2091-7. PubMed ID: 27281061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCR5 antagonism impacts vaccination response and immune profile in HIV-1 infection.
    Westrop SJ; Moyle G; Jackson A; Nelson M; Mandalia S; Imami N
    Mol Med; 2012 Oct; 18(1):1240-8. PubMed ID: 22875102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.
    Latinovic OS; Zhang J; Tagaya Y; DeVico AL; Fouts TR; Schneider K; Lakowicz JR; Heredia A; Redfield RR
    Curr HIV Res; 2016; 14(1):24-36. PubMed ID: 26354735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.
    Mills A; Mildvan D; Podzamczer D; Fätkenheuer G; Leal M; Than S; Valluri SR; Craig C; McFadyen L; Vourvahis M; Heera J; Valdez H; Rinehart AR; Portsmouth S
    J Acquir Immune Defic Syndr; 2013 Feb; 62(2):164-70. PubMed ID: 23187936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
    Cillo AR; Hilldorfer BB; Lalama CM; McKinnon JE; Coombs RW; Tenorio AR; Fox L; Gandhi RT; Ribaudo H; Currier JS; Gulick RM; Wilkin TJ; Mellors JW
    AIDS; 2015 Oct; 29(16):2121-9. PubMed ID: 26544577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256.
    Wilkin TJ; Lalama CM; McKinnon J; Gandhi RT; Lin N; Landay A; Ribaudo H; Fox L; Currier JS; Mellors JW; Gulick R; Tenorio AR
    J Infect Dis; 2012 Aug; 206(4):534-42. PubMed ID: 22740718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of maraviroc on HIV disease progression-related biomarkers.
    Romero-Sánchez MC; Machmach K; Gonzalez-Serna A; Genebat M; Pulido I; García-García M; Alvarez-Ríos AI; Ferrando-Martinez S; Ruiz-Mateos E; Leal M
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5858-64. PubMed ID: 22948867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maraviroc contributes to the restoration of the homeostasis of regulatory T-cell subsets in antiretroviral-naive HIV-infected subjects.
    Pozo-Balado MM; Rosado-Sánchez I; Méndez-Lagares G; Rodríguez-Méndez MM; Ruiz-Mateos E; Benhnia MR; Muñoz-Fernández MA; Leal M; Pacheco YM
    Clin Microbiol Infect; 2016 May; 22(5):461.e1-5. PubMed ID: 26806257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness, safety, durability and immune recovery in a retrospective, multicentre, observational cohort of ART-experienced, HIV-1-infected patients receiving maraviroc.
    Dentone C; Sterrantino G; Signori A; Cenderello G; Guerra M; De Leo P; Bartolacci V; Mantia E; Orofino G; Giacomini M; Bruzzone B; Francisci D; Di Biagio A;
    Int J STD AIDS; 2017 Oct; 28(11):1067-1073. PubMed ID: 28142395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 Antagonists.
    Flynn JK; Ellenberg P; Duncan R; Ellett A; Zhou J; Sterjovski J; Cashin K; Borm K; Gray LR; Lewis M; Jubb B; Westby M; Lee B; Lewin SR; Churchill M; Roche M; Gorry PR
    AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1220-1235. PubMed ID: 28797170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maraviroc: a review of its use in HIV infection and beyond.
    Woollard SM; Kanmogne GD
    Drug Des Devel Ther; 2015; 9():5447-68. PubMed ID: 26491256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.